Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. It develops wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; shampoo for dogs, cats, and horses under the Alosera trademark; and pet oral care solutions under the StrixNB and bluestem trademarks. The company was founded in 2001 and is based in Winnipeg, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-204-4531301
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$382,162.00
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Kane Biotech (CVE:KNE) Frequently Asked Questions
What is Kane Biotech's stock symbol?
Kane Biotech trades on the Canadian Venture Exchange (CVE) under the ticker symbol "KNE."
How were Kane Biotech's earnings last quarter?
Kane Biotech Inc (CVE:KNE) posted its earnings results on Wednesday, November, 14th. The company reported ($0.01) EPS for the quarter. The company earned $0.11 million during the quarter. View Kane Biotech's Earnings History.
When is Kane Biotech's next earnings date?
Has Kane Biotech been receiving favorable news coverage?
Media coverage about KNE stock has trended positive recently, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kane Biotech earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Kane Biotech's key competitors?
Some companies that are related to Kane Biotech include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB).
Who are Kane Biotech's key executives?
Kane Biotech's management team includes the folowing people:
- Mr. Marc Edwards, Interim CEO & Director
- Mr. Ray Dupuis, Chief Financial Officer
- Mr. Mark Ahrens-Townsend, Advisor
- Dr. Gordon Guay, Chief Scientific Officer & Member of Scientific Advisory Board
- Mr. L. Michael Coutts, Director of Bus. Devel.
How do I buy shares of Kane Biotech?
Shares of KNE and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Kane Biotech's stock price today?
One share of KNE stock can currently be purchased for approximately C$0.08.
What is Kane Biotech's official website?
How can I contact Kane Biotech?
Kane Biotech's mailing address is 162-196 Innovation Dr, WINNIPEG, MB R3T 6C5, Canada. The company can be reached via phone at +1-204-4531301.
MarketBeat Community Rating for Kane Biotech (CVE KNE)
MarketBeat's community ratings are surveys of what our community members think about Kane Biotech and other stocks. Vote "Outperform" if you believe KNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
